Enzastaurin

Overview

Enzastaurin (LY317615) is a potent, selective, and CNS-penetrant PKCβ inhibitor with an IC 50 of 6 nM, showing 6- to 20-fold selectivity over PKCα , PKCγ and PKCε .

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PKC | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10342
• CAS No.: 170364-57-5
• Molecular Formula: C32H29N5O2
• Molecular Weight: 515.61
• Purity: 99.80%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 0.83 mg/mL (1.61 mM); Clear solution
• Availability: In-stock

Source

Original product source